20 results on '"Mermershtain W"'
Search Results
2. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- Author
-
Fizazi, Karim, Tran, Namphuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez Antolin, Alfredo, Alekseev, Boris Y., Ãzgã¼roglu, Mustafa, Dingwei, Ye, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary B., Chi, Korbenfeld E, Kim N., Metrebian, S, Kaen, L, Staneloni, E, Batagelj, E, Tan, H, Hovey, E, Woo, H, Frydenberg, M, Chua, W, D’Hondt, L, Evaraert, E, Verschaeve, V, Wynendaele, W, Schrijvers, D, Waltregny, D, Whenham, N, Demey, W, Franke, F, Panhoca, R, Damião, R, Zucca, L, Da Rosa, V, Reis, R, Scalabrini, A, Nahas, W, Girotto, G, Nogueira, A, Gomes, A, Coradazzi, A, Kurteva, G, Siemens, R, Gingerich, J, Fleshner, N, Fradet, Y, Morgan, S, North, S, Saad, F, Shayegan, B, Zalewski, P, Pinochet, R, Orellana, N, Ding, Q, Ye, Z, Xie, L, Du, C, Chen, Z, Huang, Y, Sun, Z, Li, H, Jin, J, Li, C, Wan, B, Tian, Y, Zhou, F, Xie, K, Yao, X, Qiu, M, Zou, Q, Na, Y, Sun, Y, Xue, B, Ma, L, Martinez, C, Salazar, M, Larios, C, Solano, S, Pavlik, I, Brodak, M, Hora, M, Büchler, T, Borre, M, Johansen, J, Mejlholm, I, Poulsen, M, Wittendorf, He, Tammela, T, Vaarala, M, Theodore, C, Staudacher, L, Villers, A, Laplaige, P, Suttman, H, Steuber, T, Natale, S, Jones, R, Tran, A, Mazhar, D, Mills, J, Nyirady, P, Salamon, C, Torzsok, F, Feher, J, Géczi, L, Lakatos, A, Keizman, D, Sella, A, Frank, S, Peer, A, Rosenbaum, E, Berger, R, Mermershtain, W, Carteni, G, Tonini, G, De Giorgi, U, Facchini, G, Berruti, Alfredo, Bracarda, S, Basso, U, Galli, L, Tortora, G, Alietta, M, Fukasawa, S, Suzuki, H, Hasumi, H, Tsuchiya, T, Uemura, H, Kanayama, H, Hashine, K, Sato, F, Matsumoto, H, Oya, M, Lee, Jl, Park, S, Keam, B, Yun, H, Kim, Y, Kang, B, Lee, K, Kim, C, Saad, M, Sundram, M, Calvo, D, Moreno, R, Rodriquez, J, Hernandez, C, van den Berg, H, De La Rosett, J, Van Moorse, R, Hunting, J, Hendriks, M, Kueppers, F, Gilling, P, Beaven, A, Holmes, M, Jassem, J, Oszukowska, E, Niezabitowski, J, Jaxa Larecka, D, Chwalinski, M, Swiniarski, P, Silva, C, Conceicãoa, P, Fraga, A, Mauricio, J, Rodrigues, T, Pinheiro, L, Lima, E, Palma Dos Reis, J, Volovat, C, Jinga, V, Harza, M, Alyasova, A, Budnik, N, Bychkov, Y, Izmaylov, A, Khvorosten, D, Matveev, V, Novsov, A, Vladimirov, V, Tevs, D, Sheveleva, L, Bulanov, A, Semenov, A, Fadeeva, N, Kulikov, E, Emelyanov, S, Karyakin, O, Shirinkin, V, Shkolnik, M, Lykov, A, Skopin, P, Kopyltsov, E, Mincik, I, Mir, O, Kliment, J, Mikurcik, E, Gajdos, M, Milichovsky, I, Malan, J, Bahlmann, J, Moshokoa, E, Madlala, T, Coetzee, L, Ribal, M, Miñana, B, Martinez Breijo, S, Carballido, J, Olmos, D, Requena, M, Morote, J, Damber, Je, Haggman, M, Nyman, C, Ljungberg, B, Bjartell, A, Ozen, H, Beduk, Y, Sozen, S, Cetinkaya, M, Ozyurt, M, Tansug, Z, Mungan, A, Tanidir, Y, Toktas, M, Hotko, E, Stus, V, Lyulko, O, Vinnyk, Y, Shparyk, Y, Sakalo, V, Bondarenko, I, Paramonov, V, Khareba, G, Hodos, V., Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'oncologie médicale
- Subjects
Adult ,Male ,medicine.medical_specialty ,Prednisolone ,Kirurgia, anestesiologia, tehohoito, radiologia - Surgery, anesthesiology, intensive care, radiology ,Abiraterone Acetate ,030232 urology & nephrology ,Urology ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,Prednisone ,Antineoplastic Combined Chemotherapy Protocols ,80 and over ,medicine ,Humans ,Aged ,Aged, 80 and over ,Androgen Antagonists ,Middle Aged ,Neoplasm Metastasis ,Prostatic Neoplasms ,Steroid 17-alpha-Hydroxylase ,Survival Analysis ,Medicine (all) ,Gynecology ,business.industry ,Apalutamide ,Abiraterone acetate ,General Medicine ,medicine.disease ,Interim analysis ,Clinical trial ,Darolutamide ,chemistry ,030220 oncology & carcinogenesis ,business ,medicine.drug - Abstract
Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 patients to receive either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy plus dual placebos (the placebo group). The two primary end points were overall survival and radiographic progression-free survival. After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the median overall survival was significantly longer in the abiraterone group than in the placebo group (not reached vs. 34.7 months) (hazard ratio for death, 0.62; 95% confidence interval [CI], 0.51 to 0.76; P
- Published
- 2017
- Full Text
- View/download PDF
3. Massive cavitation of solid pulmonary metastatic lesions in a breast cancer patient: a case report
- Author
-
Mermershtain, W., Schulman, H., Hertzanu, Y., and Cohen, Y.
- Published
- 2002
4. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases:analysis of an international multicenter database
- Author
-
Keizman, D, Fosboel, M O, Reichegger, H, Peer, A, Rosenbaum, E, Desax, M-C, Neiman, V, Petersen, P M, Mueller, J, Cathomas, R, Gottfried, M, Dresler, H, Sarid, D, Mermershtain, W, Rouvinov, K, Mortensen, J, Gillessen, S, Daugaard, G, Omlin, A, Keizman, D, Fosboel, M O, Reichegger, H, Peer, A, Rosenbaum, E, Desax, M-C, Neiman, V, Petersen, P M, Mueller, J, Cathomas, R, Gottfried, M, Dresler, H, Sarid, D, Mermershtain, W, Rouvinov, K, Mortensen, J, Gillessen, S, Daugaard, G, and Omlin, A
- Abstract
BACKGROUND: The imaging response to radium-223 therapy is at present poorly described. We aimed to describe the imaging response to radium-223 treatment.METHODS: We retrospectively evaluated the computed tomography (CT) and bone scintigraphy response of metastatic castration-resistant prostate cancer (CRPC) patients treated with radium-223, in eight centers in three countries.RESULTS: A total of 130 patients were included, the majority (n=84, 65%) received radium-223 post docetaxel. Thirty-four of 99 patients with available data (34%) received concomitant abiraterone or enzalutamide. A total of 54% (n=70) patients completed the planned six injections of radium-223. In patients with available data, a transient increase in bone metastases-related pain was observed in 27% (n=33/124) and an improvement of bone metastases-related pain on treatment with radium-223 was noted in 49% of patients (n=61/124). At 3 and 6 months of treatment with radium-223, bone imaging showed stable disease in 74% (n=84/113) and 94% of patients (n=93/99) with available data, respectively. An increase in the number of bone lesions was documented at 3 months compared with baseline in 26% (n=29/113) and at 6 months compared with 3 months in 6% of patients (n=6/99), respectively. Radiological extraskeletal disease progression occurred in 46% of patients (n=57/124) with available CT data at 3 and/or 6 months.CONCLUSIONS: Progression of bone metastases during radium-223 therapy is uncommon. A bone flare (pain and/or radiological) may be noted during the first 3 months, and should not be confused with progression. Imaging by CT scan should be considered after three and six doses of radium-223 to rule out extraskeletal disease progression.
- Published
- 2017
5. Patients (pts) with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with Nivolumab (Nivo) based immunotherapy as advanced treatment (ATL) line: analysis of a national early access program (EAP)
- Author
-
Peer, A., primary, Savion, K., additional, Rouvinov, K., additional, Leibowitz-Amit, R., additional, Berger, R., additional, Sella, A., additional, Neiman, V., additional, Rosenbaum, E., additional, Mermershtain, W., additional, Neumann, A., additional, Kolin, M., additional, Perets, R., additional, and Keizman, D., additional
- Published
- 2017
- Full Text
- View/download PDF
6. Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib
- Author
-
Neiman, V., primary, Keizman, D., additional, Sarid, D., additional, Lee, J.-L., additional, Sella, A., additional, Gottfried, M., additional, Hammers, H., additional, Eisenberger, M., additional, Carducci, M., additional, Sinibaldi, V., additional, Rosenbaum, E., additional, Peer, A., additional, Neumann, A., additional, Mermershtain, W., additional, Rouvinov, K.R., additional, Berger, R., additional, and Yildiz, I., additional
- Published
- 2016
- Full Text
- View/download PDF
7. 911P - Patients (pts) with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with Nivolumab (Nivo) based immunotherapy as advanced treatment (ATL) line: analysis of a national early access program (EAP)
- Author
-
Peer, A., Savion, K., Rouvinov, K., Leibowitz-Amit, R., Berger, R., Sella, A., Neiman, V., Rosenbaum, E., Mermershtain, W., Neumann, A., Kolin, M., Perets, R., and Keizman, D.
- Published
- 2017
- Full Text
- View/download PDF
8. 831P - Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib
- Author
-
Neiman, V., Keizman, D., Sarid, D., Lee, J.-L., Sella, A., Gottfried, M., Hammers, H., Eisenberger, M., Carducci, M., Sinibaldi, V., Rosenbaum, E., Peer, A., Neumann, A., Mermershtain, W., Rouvinov, K.R., Berger, R., and Yildiz, I.
- Published
- 2016
- Full Text
- View/download PDF
9. Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model
- Author
-
Vainas, O, primary, Ariad, S, additional, Amir, O, additional, Mermershtain, W, additional, Vainstein, V, additional, Kleiman, M, additional, Inbar, O, additional, Ben-Av, R, additional, Mukherjee, A, additional, Chan, S, additional, and Agur, Z, additional
- Published
- 2012
- Full Text
- View/download PDF
10. Combined acute aortic thrombosis and metastatic spinal cord compression causing paraplegia in a patient with small-cell lung carcinoma(SCLC)
- Author
-
Mermershtain, W., primary, Szendro, G., additional, Golcman, L., additional, and Ariad, S., additional
- Published
- 1996
- Full Text
- View/download PDF
11. Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.
- Author
-
Rouvinov K, Levanon E, Peer A, Sarfaty M, Sarid D, Neiman V, Grikshtas E, Rosenbaum E, Kushnir I, Talmor B, Friger M, Zarbiv Y, Gez E, Dresler H, Shalata W, Meirovitz A, Shrem NS, Yakobson A, Mermershtain W, and Keizman D
- Abstract
Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 months overall survival. These FGFR genomic alterations are uncommon. Thus, real-world data on erdafitinb use is scant. We herein describe erdafitinib treatment outcome in a real world patient cohort., Methods: We retrospectively reviewed the data of patients treated with erdafitinib from 9 Israeli medical centers., Results: Twenty-five patients with metastatic urothelial carcinoma (median age 73, 64% male, 80% with visceral metastases) were treated with erdafitinib between January 2020 to October 2022. A clinical benefit (complete response 12%, partial response 32%, stable disease 12%) was seen in 56%. Median progression-free survival was 2.7 months, and median overall survival 6.73 months. Treatment related toxicity ≥ grade 3 occurred in 52%, and 32% discontinued therapy due to adverse events., Conclusions: Erdafitinib therapy is associated with a clinical benefit in the real world setting, and associated with similar toxicity as reported in prospective clinical trials., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Rouvinov, Levanon, Peer, Sarfaty, Sarid, Neiman, Grikshtas, Rosenbaum, Kushnir, Talmor, Friger, Zarbiv, Gez, Dresler, Shalata, Meirovitz, Shrem, Yakobson, Mermershtain and Keizman.)
- Published
- 2023
- Full Text
- View/download PDF
12. Prophylactic Breast Irradiation for Prevention of Bicalutamide-induced Painful Gynecomastia in Patients with Low- and Intermediate-risk Prostate Cancer.
- Author
-
Chernomordikov E, Rouvinov K, Mermershtain W, and Lavrenkov K
- Subjects
- Humans, Male, Androgen Antagonists adverse effects, Pain, Prospective Studies, Gynecomastia chemically induced, Gynecomastia prevention & control, Prostatic Neoplasms radiotherapy
- Abstract
Background: Bicalutamide monotherapy (BMT) is an option for androgen deprivation therapy (ADT) in patients with low- and intermediate-risk prostate cancer (LIR-PC). Painful gynecomastia (PG) is a common side effect of BMT. Few therapeutic options are available for preventing BMT-induced PG., Objectives: To assess the efficacy and side effects of single fraction (SF) prophylactic breast irradiation (PBI) to prevent painful gynecomastia (PG) in patients LIR-PC treated with BMT., Methods: We reviewed the results of bilateral PBI in a prospective cohort of LIR-PC patients who received 150 mg bicalutamide daily as a first-line treatment for at least 12 months. A single fraction of 8 Gy was administered to both breasts by a stationary field of 10 × 10 cm, using 10-15 MeV electron beam. PBI was commenced on the same day as BMT, but prior to the first dose of bicalutamide. A radiotherapy treatment plan was designed to cover breast tissue by the 90% isodose line. Subsequent monthly physical examinations were scheduled for all patients during the first year of BMT to evaluate any PG symptoms., Results: Seventy-six patients received BMT and PBI, 80% (61/76) showed no signs of PG; 20% (15/76) experienced mild gynecomastia. The main adverse effect of PBI was grade 1 radiation dermatitis., Conclusions: PBI using a SF of 8 Gy is an effective, safe, and low-cost strategy for the prevention of BMT-induced PG in LIR-PC patients.
- Published
- 2023
13. Testicular Metastasis from Renal Cell Carcinoma: A Case Report and Review of the Literature.
- Author
-
Rouvinov K, Neulander EZ, Kan E, Asali M, Ariad S, and Mermershtain W
- Abstract
Testicular metastases from renal cell carcinoma (RCC) are extremely rare. To the best of our knowledge, only 33 cases have been described in the literature. Most of the reported cases are of unilateral testicular metastasis from RCC. We report a case of metachronous ipsilateral testicular metastasis from RCC in a 78-year-old man 6 years after nephrectomy. Scrotal ultrasonography showed a 4 × 5 cm mass in the right testis. Right inguinal orchiectomy was performed for diagnosis. Computed tomography revealed liver and lung metastases. First-line therapy with sunitinib was started in November 2016 for metastatic RCC.
- Published
- 2017
- Full Text
- View/download PDF
14. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
- Author
-
Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H, Eisenberger MA, Carducci MA, Sinibaldi V, Neiman V, Rosenbaum E, Peer A, Neumann A, Mermershtain W, Rouvinov K, Berger R, and Yildiz I
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell pathology, Disease-Free Survival, Female, Humans, Kidney Neoplasms mortality, Kidney Neoplasms pathology, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Sunitinib, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Indoles therapeutic use, Kidney Neoplasms drug therapy, Pyrroles therapeutic use
- Abstract
Background: Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC., Methods: Records from mchRCC patients treated with first-line sunitinib in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC patients were individually matched to mccRCC patients. We compared the clinical benefit rate, progression-free survival (PFS), and overall survival (OS) between the groups., Results: Between 2004 and 2014, 36 patients (median age, 64 years; 47% male) with mchRCC were treated with first-line sunitinib. Seventy-eight percent achieved a clinical benefit (partial response + stable disease). Median PFS and OS were 10 and 26 months, respectively. Factors associated with PFS were the Heng risk (hazard ratio [HR], 3.3; p = .03) and pretreatment neutrophil-to-lymphocyte ratio (NLR) >3 (HR, 0.63; p = .02). Factors associated with OS were the Heng risk (HR, 4.1; p = .04), liver metastases (HR, 3.8; p = .03), and pretreatment NLR <3 (HR, 0.55; p = .03). Treatment outcome was not significantly different between mchRCC patients and individually matched mccRCC patients. In mccRCC patients (p value versus mchRCC), 72% achieved a clinical benefit (p = .4) and median PFS and OS were 9 (p = .6) and 25 (p = .7) months, respectively., Conclusion: In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The Heng risk and pretreatment NLR may be associated with PFS and OS., Implications for Practice: Data on the activity of sunitinib in metastatic chromophobe renal cell carcinoma (mchRCC) are limited. This study analyzed the activity of sunitinib in a cohort of mchRCC patients. Of 36 patients with mchRCC who were treated with first-line sunitinib, 78% achieved a clinical benefit. Median PFS and OS were 10 and 26 months, respectively. Treatment outcome was not significantly different between mchRCC patients and individually matched metastatic clear cell RCC patients., Competing Interests: of potential conflicts of interest may be found at the end of this article., (©AlphaMed Press.)
- Published
- 2016
- Full Text
- View/download PDF
15. Ipilimumab Treatment-Induced Distal Esophageal Dissection in a Patient with Advanced Prostate Cancer.
- Author
-
Yardeni D, Galante O, Fuchs L, Munteanu D, Mermershtain W, Shaco-Levy R, and Almog Y
- Subjects
- Aged, Antineoplastic Agents administration & dosage, Esophageal Diseases pathology, Humans, Ipilimumab administration & dosage, Male, Prostatic Neoplasms pathology, Antineoplastic Agents adverse effects, Esophageal Diseases chemically induced, Ipilimumab adverse effects, Prostatic Neoplasms drug therapy
- Published
- 2016
16. Adjuvant brachytherapy for Stage IB Grade 2 endometrial carcinoma: Multivariate analysis of a single institution experience.
- Author
-
Tokar M, Meirovich M, Bobilev D, and Mermershtain W
- Abstract
Objective: The aim was to investigate the value of postoperative brachytherapy for patients with Stage IB, Grade 2 endometrial carcinoma., Patients and Methods: Forty-six patients with Stage IB, Grade 2 endometrial carcinoma, were treated with simple hysterectomy and bilateral oophorectomy in our institution. The mean age was 63 (range, 42-81). Surgical staging, defined as peritoneal washing and pelvic lymph node sampling was performed in 73% of patients. Twenty-two patients (47%) received a postoperative intravaginal brachytherapy (IVRT), and 24 patients (53%) were followed-up without additional treatment., Results: The median follow-up was 60 months. The 5-year overall survival for irradiated and nonirradiated patients, was 83.5 and 94.7%, respectively. Four patients (8.7%) developed relapse, two in the group of postoperative IVRT and 2 in the follow-up only group. Multivariate analysis demonstrated a borderline association (P = 0.06) between lower uterine segment involvement and poor pelvic-vaginal control. The presence of GOG #99 high-risk features did not affect the pelvic control rate., Conclusion: According to our experience and previously published data, most patients with FIGO Stage IB, Grade 2 endometrial carcinoma may be cured with surgery alone.
- Published
- 2016
- Full Text
- View/download PDF
17. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
- Author
-
Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, Eisenberger MA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, Weitzen R, and Berger R
- Subjects
- Adult, Aged, Angiogenesis Inhibitors therapeutic use, Artifacts, Carcinoma, Renal Cell psychology, Disease Progression, Disease-Free Survival, Female, Humans, Kidney Neoplasms psychology, Male, Middle Aged, Reproducibility of Results, Retrospective Studies, Sunitinib, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Clinical Trials as Topic psychology, Indoles therapeutic use, Kidney Neoplasms drug therapy, Pyrroles therapeutic use
- Abstract
Purpose: Studies suggested the existence of a 'trial effect', in which for a given treatment, participation in a clinical trial is associated with a better outcome. Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). We aimed to study the effect of clinical trial participation on the outcome of mRCC patients treated with sunitinib, which at present, is poorly defined., Materials and Methods: The records of mRCC patients treated with sunitinib between 2004-2013 in 7 centers across 2 countries were reviewed. We compared the response rate (RR), progression free survival (PFS), and overall survival (OS), between clinical trial participants (n=49) and a matched cohort of non-participants (n=49) who received standard therapy. Each clinical trial participant was individually matched with a non-participant by clinicopathologic factors. PFS and OS were determined by Cox regression., Results: The groups were matched by age (median 64), gender (male 67%), Heng risk (favorable 25%, intermediate 59%, poor 16%), prior nephrectomy (92%), RCC histology (clear cell 86%), pre-treatment NLR (>3 in 55%, n=27), sunitinib induced hypertension (45%), and sunitinib dose reduction/treatment interruption (41%). In clinical trial participants versus non-participants, RR was partial response/stable disease 80% (n=39) versus 74% (n=36), and progressive disease 20% (n=10) versus 26% (n=13) (p=0.63, OR 1.2). The median PFS was 10 versus 11 months (HR=0.96, p=0.84), and the median OS 23 versus 24 months (HR=0.97, p=0.89)., Conclusions: In mRCC patients treated with sunitinib, the outcome of clinical trial participants was similar to that of non-participants who received standard therapy.
- Published
- 2016
- Full Text
- View/download PDF
18. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
- Author
-
Livne-Segev D, Gottfried M, Maimon N, Peer A, Neumann A, Hayat H, Kovel S, Sella A, Mermershtain W, Rouvinov K, Boursi B, Weitzen R, Berger R, and Keizman D
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Carcinoma, Renal Cell pathology, Cohort Studies, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Indoles administration & dosage, Indoles adverse effects, Israel, Kidney Neoplasms pathology, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Pyrroles administration & dosage, Pyrroles adverse effects, Retrospective Studies, Sunitinib, Survival Rate, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Indoles therapeutic use, Kidney Neoplasms drug therapy, Pyrroles therapeutic use
- Abstract
Background: The VEGFR/PDGFR inhibitor sunitinib was approved in Israel in 2008 for the treatment of metastatic renal cell carcinoma (mRCC), based on an international trial. However, the efficacy of sunitinib treatment in Israeli mRCC patients has not been previously reported., Objectives: To report the outcome and associated factors of sunitinib treatment in a large cohort of Israeli mRCC patients., Methods: We conducted a retrospective study of an unselected cohort of mRCC patients who were treated with sunitinib during the period 2006-2013 in six Israeli hospitals. Univariate and multivariate analyses were performed to determine the association between treatment outcome and clinicopathologic factors., Results: We identified 145 patients; the median age was 65 years, 63% were male, 80% had a nephrectomy, and 28% had prior systemic treatment. Seventy-nine percent (n = 115) had clinical benefit (complete response 5%, n = 7; partial response 33%, n = 48; stable disease 41%, n = 60); 21% (n = 30) were refractory to treatment. Median progression-free survival (PFS) was 12 months and median overall survival 21 months. Factors associated with clinical benefit were sunitinib-induced hypertension: [odds ratio (OR) 3.6, P = 0.042] and sunitinib dose reduction or treatment interruption (OR 2.4, P = 0.049). Factors associated with PFS were female gender [hazard ratio (HR) 2, P = 0.0041, pre-sunitinib treatment neutrophil-to-lymphocyte ratio < or = 3 (HR 2.19, P = 0.002), and active smoking (HR 0.19, P < 0.0001). Factors associated with overall survival were active smoking (HR 0.25, P < 0.0001) and sunitinib-induced hypertension (HR 0.48, P = 0.005). To minimize toxicity, the dose was reduced or the treatment interrupted in 39% (n = 57)., Conclusions: The efficacy of sunitinib treatment for mRCC among Israeli patients is similar to that in international data.
- Published
- 2014
19. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
- Author
-
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, and Carducci MA
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell pathology, Female, Humans, Kidney Neoplasms pathology, Male, Middle Aged, Multicenter Studies as Topic, Multivariate Analysis, Neoplasm Metastasis, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Sunitinib, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Indoles therapeutic use, Kidney Neoplasms drug therapy, Pyrroles therapeutic use, Smoking adverse effects
- Abstract
Background: Obesity, smoking, hypertension, and diabetes are risk factors for renal cell carcinoma development. Their presence has been associated with a worse outcome in various cancers. We sought to determine their association with outcome of sunitinib treatment in metastatic renal cell carcinoma (mRCC)., Methods: An international multicenter retrospective study of sunitinib-treated mRCC patients was performed. Multivariate analyses were performed to determine the association between outcome and the pretreatment status of smoking, body mass index, hypertension, diabetes, and other known prognostic factors., Results: Between 2004 and 2013, 278 mRCC patients were treated with sunitinib: 59 were active smokers, 67 were obese, 73 were diabetic, and 165 had pretreatment hypertension. Median progression-free survival (PFS) was 9 months, and overall survival (OS) was 22 months. Factors associated with PFS were smoking status (past and active smokers: hazard ratio [HR]: 1.17, p = .39; never smokers: HR: 2.94, p < .0001), non-clear cell histology (HR: 1.62, p = .011), pretreatment neutrophil-to-lymphocyte ratio >3 (HR: 3.51, p < .0001), use of angiotensin system inhibitors (HR: 0.63, p = .01), sunitinib dose reduction or treatment interruption (HR: 0.72, p = .045), and Heng risk (good and intermediate risk: HR: 1.07, p = .77; poor risk: HR: 1.87, p = .046). Factors associated with OS were smoking status (past and active smokers: HR: 1.25, p = .29; never smokers: HR: 2.7, p < .0001), pretreatment neutrophil-to-lymphocyte ratio >3 (HR: 2.95, p < .0001), and sunitinib-induced hypertension (HR: 0.57, p = .002)., Conclusion: Active smoking may negatively affect the PFS and OS of sunitinib-treated mRCC. Clinicians should consider advising patients to quit smoking at initiation of sunitinib treatment for mRCC.
- Published
- 2014
- Full Text
- View/download PDF
20. Serous papillary adenocarcinoma of the rete testis: unusual ultrasonography and pathological findings.
- Author
-
Mermershtain W, Vardi N, Gusakova I, and Klein J
- Subjects
- Adult, Cystadenocarcinoma, Serous surgery, Humans, Lymph Node Excision, Male, Neoplasm Staging, Orchiectomy, Testicular Neoplasms surgery, Ultrasonography, Cystadenocarcinoma, Serous diagnostic imaging, Cystadenocarcinoma, Serous pathology, Rete Testis, Testicular Neoplasms diagnostic imaging, Testicular Neoplasms pathology
- Abstract
We report a case of serous papillary adenocarcinoma of the rete testis in a 22-year-old man. Adenocarcinoma of the rete testis is highly resistant to radiotherapy and any known chemotherapeutic regimen. We recommend radical orchiectomy At last follow up, the patient was well, without any evidence of recurrence, ten years after surgery.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.